In addition to HIF-1, NF-κB is also involved in the development of chemoresistance to anti-cancer reagents in many tumors [32,33]; therefore, simultaneous targeting of HIF and NF-κB might be the ideal approach to treating chemoresistant cancers. Here, NFKB1 is linked to cancer.